FindTrial
Sign In

Unveiling ERlow Breast Cancer in India: Insights from a Multicenter Registry and Collaborative Centers on Clinicopathological Characteristics and Clinical Outcomes"

Real world data on clinicopathological characteristics and clinical outcomes of ERlow breast cancer from an Indian Multicenter registry and collaborative centers - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/11/060352
Enrollment
200
Registered
2023-11-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C508- Malignant neoplasm of overlappingsites of breast

Interventions

Intervention1: NIL: NIL

Sponsors

Dr ASHWIN OOMMEN PHILIPS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patient > 18 years of age 2) Patients with a histopathological proven diagnosis of breast cancer and with an IHC report of ER low positivity ( ER 1-10% ,PR 1-10%, Her 2 negative)

Exclusion criteria

Exclusion criteria: 1. 2. Patients with breast cancer who are ER negative or High ER positive ( ER-0%, PR-0%, ER/PR >10%) 3. In case discrepancy between the ER status pre surgery and post surgery- the patients having high ER at any time will be excluded. 4. Her 2-3+ by IHC or FISH positive cases

Design outcomes

Primary

MeasureTime frame
1)To evaluate the the clinicopathological characteristics and clinical outcomes of ERlow breast cancer. 2)To determine the progression free survival (PFS) for patients with ERlow breast cancer. 3)To determine the overall survival (OS) for patients with ERlow breast cancer. Timepoint: 1 YEAR, 2 YEARS, 3 YEARS , 4 YEARS , 5 YEARS—

Secondary

MeasureTime frame
MODES OF TREATMENTTimepoint: 6months, 12 months, 18 months—

Countries

India

Contacts

Public ContactASHWIN OOMMEN PHILIPS

Christian Medical College, Ludhiana

drashphilsmog@gmail.com9003635373

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026